Maxigesic IV Drug Insight and Market Forecast – 2032

Maxigesic IV Drug Insight and Market Forecast – 2032

“Maxigesic IV Drug Insight and Market Forecast – 2032” report provides comprehensive insights about Maxigesic IV for Postoperative Pain in the 7MM. A detailed picture of the Maxigesic IV for Postoperative Pain in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019–2032 is provided in this report along with a detailed description of the Maxigesic IV for Postoperative Pain. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the Maxigesic IV market forecast, analysis for Postoperative Pain in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about emerging therapies in Postoperative Pain.

Drug Summary

Maxigesic IV, a novel, patented, dual mode-of-action non-opioid pain treatment, is a unique combination of Paracetamol (known as acetaminophen in the US) 1000mg + Ibuprofen 300mg solution for infusion for use post-operatively in hospitals for patients for whom the use of oral analgesics is limited.

Maxigesic reduces fever and provides temporary relief of pain associated with headache, migraine headache, tension headache, sinus pain, toothache, dental procedures, backache, sore throat, arthritis, tennis elbow, period pain, muscular pain, rheumatic pain, aches and pains associated with colds and flu. The drug is a unique patented combination of paracetamol and ibuprofen, proven to provide fast and effective relief from a wide range of pain symptoms (This information is for New Zealand only). The product has obtained marketing authorisations in 17 European countries, launched in Australia, New Zealand and United Arab Emirates, and multiple license and distribution agreements signed to accelerate roll-out and commercialisation in Europe and Hong Kong. Second Phase III study successfully completed to support regulatory submission in the US.

This specific combination is designed to allow the maximum daily dose of Paracetamol and Ibuprofen, and to allow for the effect of Paracetamol on Phenylephrine – when combined the level of Phenylephrine crossing into the bloodstream effectively doubles.

In adults and children over 12 years, the usual dosage is one to two tablets taken every six hours, as required, up to a maximum of eight tablets in 24 hours. Children under 12 years: It is not recommended for children under 12 years of age. It is not recommended to take more than eight tablets in a 24-hour period until the doctor prescribes a different dose.

Scope of the Report

The report provides insights into:

A comprehensive product overview including the Maxigesic IV description, mechanism of action, dosage and administration, research and development activities in Postoperative Pain.

Elaborated details on Maxigesic IV regulatory milestones and other development activities have been provided in this report.

The report also highlights the Maxigesic IV research and development activity in Postoperative Pain details across the United States, Europe and Japan.

The report also covers the patents information with expiry timeline around Maxigesic IV.

The report contains forecasted sales of Maxigesic IV for Postoperative Pain till 2032.

Comprehensive coverage of the late-stage emerging therapies for Postoperative Pain.

The report also features the SWOT analysis with analyst views for Maxigesic IV in Postoperative Pain.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Maxigesic IV Analytical Perspective by DelveInsight

In-depth Maxigesic IV Market Assessment

This report provides a detailed market assessment of Maxigesic IV in Postoperative Pain in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2022 to 2032.

Maxigesic IV Clinical Assessment

The report provides the clinical trials information of Maxigesic IV for Postoperative Pain covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

In the coming years, the market scenario for Postoperative Pain is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.

The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Maxigesic IV dominance.

Other emerging products for Postoperative Pain are expected to give tough market competition to Maxigesic IV and launch of late-stage emerging therapies in the near future will significantly impact the market.

A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Maxigesic IV in Postoperative Pain.

Our in-depth analysis of the forecasted sales data of Maxigesic IV from 2022 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Maxigesic IV in Postoperative Pain.

Key Questions

What is the product type, route of administration and mechanism of action of Maxigesic IV?

What is the clinical trial status of the study related to Maxigesic IV in Postoperative Pain and study completion date?

What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Maxigesic IV development?

What are the key designations that have been granted to Maxigesic IV for Postoperative Pain?

What is the forecasted market scenario of Maxigesic IV for Postoperative Pain?

What are the forecasted sales of Maxigesic IV in the 7MM, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?

What are the other emerging products available in Postoperative Pain and how are they giving competition to Maxigesic IV for Postoperative Pain?

Which are the late-stage emerging therapies under development for the treatment of Postoperative Pain?